Versartis, a US-based biotechnology company to treat growth hormone deficiency backed by Amunix, has raised $25m in its series C round.
Venture capital firms Aisling Capital, which led the round, Index Ventures, New Leaf Venture Partners and Advent Venture Partners provided the money to Versatis. Index’s life sciences fund has two medical companies, GlaxoSmithKline and Johnson & Johnson, providing half its money.
In February last year, Versartis raised $21m in its series B round from a company including drugs group Amunix.
Alongside Amunix are venture capital (VC) firms New Leaf Venture Partners Advent Venture Partners and Index Ventures.
In June 2009, Versartis, raised $11m (with an option to add a further $5m) in its series A round from Amunix and Index Ventures.
Versartis was started as a joint venture between Amunix and Index to exploit Amunix’s recombinant PEGylation (rPEG) technology.